AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2689399 — intervention group
Group type: COMPARATOR
Intervention: Standard photon radiotherapy (60 and 70 Gy)
Number of subjects: 163
Study 2689399 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy and chemotherapy (60 Gy + BCNU and 60 Gy + MeCCNU + DTIC)
Number of subjects: 163
Study 2689399 — intervention group
Group type: EXPERIMENTAL
Intervention: Photon irradiation plus neutron boost
Number of subjects: 163
Study 30120605 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity glass ionomer (EQUIA Fil, GC)
Number of subjects: 134
Study 30120605 — intervention group
Group type: COMPARATOR
Intervention: Composite resin (G‐aenial, GC)
Number of subjects: 134
Study 28317458 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR-guided coronary revascularization
Number of subjects: 2492
Study 28317458 — intervention group
Group type: COMPARATOR
Intervention: FFR-guided coronary revascularization
Number of subjects: 2492
Study 26183105 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC group (pantoprazole, amoxicillin, clarithromycin for 14 days)
Number of subjects: 5
Study 26183105 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM group (pantoprazole, amoxicillin, metronidazole for 14 days)
Number of subjects: 5
Study 26183105 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-containing group (pantoprazole, bismuth subsalicylate, tetracycline, metronidazole for 14 days)
Number of subjects: 5
Study 26183105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential group (pantoprazole and amoxicillin for 5 days, followed by pantoprazole, tetracycline, and metronidazole for the next 5 days)
Number of subjects: 5
Study 26183105 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant group (pantoprazole, amoxicillin, tetracycline, and metronidazole for 10 days)
Number of subjects: 5
Study 23542218 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT-I) administered 3 to 9 months poststroke
Number of subjects: 222
Study 23542218 — intervention group
Group type: COMPARATOR
Intervention: Constraint-Induced Movement Therapy (CIMT-D) administered 15 to 21 months poststroke
Number of subjects: 222
Study 21953653 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training program; 60-minute interactive session supported by a clinical guide.
Number of subjects: 70
Study 21953653 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training).
Number of subjects: 70
Study 18173581 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure and interactive multimedia intervention for visual health (15 weeks)
Number of subjects: 70
Study 18173581 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 17181922 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential currents (IFT) administered for 10 minutes daily for 5 days per week for two weeks
Number of subjects: 120
Study 17181922 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal therapy (HT) administered for 40 minutes daily for 5 days per week for two weeks
Number of subjects: 120
Study 17181922 — intervention group
Group type: COMPARATOR
Intervention: Sham HT administered for 40 minutes daily for 5 days per week for two weeks
Number of subjects: 120
Study 14572947 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific preoperative information
Number of subjects: 60
Study 14572947 — intervention group
Group type: COMPARATOR
Intervention: Routine preoperative information
Number of subjects: 60
Study 10937313 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomically detailed dolls
Number of subjects: 0
Study 10937313 — intervention group
Group type: COMPARATOR
Intervention: Genital examination
Number of subjects: 0
Study 10937313 — intervention group
Group type: COMPARATOR
Intervention: No genital examination
Number of subjects: 0
Study 8738112 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (FO, 22 ml daily, containing 4.6 g of n‐3 fatty acids)
Number of subjects: 10
Study 8738112 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil (G, 900 mg daily)
Number of subjects: 10
Study 8738112 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (FO, 22 ml daily)
Number of subjects: 10
Study 8738112 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither FO nor G
Number of subjects: 10
Study 1568520 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg O‐(beta‐hydroxyethyl)rutosides orally twice daily
Number of subjects: 97
Study 1568520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 3901421 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) administered at a rate of 2.5-5.0 ng/kg/min
Number of subjects: 26
Study 3901421 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glycine buffer)
Number of subjects: 26
Study 30351169 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding education video
Number of subjects: 816
Study 30351169 — intervention group
Group type: COMPARATOR
Intervention: Prenatal nutrition video
Number of subjects: 816
Study 27286693 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten Free Diet (GFD)
Number of subjects: 80
Study 27286693 — intervention group
Group type: COMPARATOR
Intervention: Regular Diet (RD)
Number of subjects: 80
Study 24913683 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid (interactive CD-ROM)
Number of subjects: 178
Study 24913683 — intervention group
Group type: COMPARATOR
Intervention: Regular information from the surgeon
Number of subjects: 178
Study 23145404 — intervention group
Group type: EXPERIMENTAL
Intervention: Case conferences
Number of subjects: 17
Study 20521882 — intervention group
Group type: EXPERIMENTAL
Intervention: +1.00 D reading addition
Number of subjects: 22
Study 20521882 — intervention group
Group type: COMPARATOR
Intervention: +2.00 D reading addition
Number of subjects: 22
Study 18520448 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (live, oral)
Number of subjects: 5098
Study 18520448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5098
Study 15932357 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived physical status at homecoming and at 12 months after GBS onset
Number of subjects: 90
Study 15932357 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived impact of GBS on daily life and social well-being
Number of subjects: 90
Study 14580131 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A
Number of subjects: 10
Study 14580131 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A plus casting
Number of subjects: 10
Study 10963018 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaphonologically (MET) therapy
Number of subjects: 61
Study 10963018 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulation‐based (ART) therapy
Number of subjects: 61
Study 10963018 — intervention group
Group type: COMPARATOR
Intervention: Control group (normally speaking children)
Number of subjects: 61
Study 10963018 — intervention group
Group type: EXPERIMENTAL
Intervention: ART therapy
Number of subjects: 61
Study 10963018 — intervention group
Group type: EXPERIMENTAL
Intervention: MET therapy
Number of subjects: 61
Study 8855091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 600 mg/day for 20 days
Number of subjects: 16
Study 8855091 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 20 days
Number of subjects: 16
Study 1595916 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with plain bupivacaine
Number of subjects: 22
Study 1595916 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with plain bupivacaine
Number of subjects: 22
Study 1595916 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgery or anesthesia)
Number of subjects: 22
Study 6091476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g preoperative dose, placebo at 8 and 16 hours later)
Number of subjects: 127
Study 6091476 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (three 1 g doses over 16 hours)
Number of subjects: 127
Study 6091476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 127
Study 6091476 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 127
Study 6091476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone and Cefazolin
Number of subjects: 127
Study 31370809 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg paricalcitol
Number of subjects: 36
Study 31370809 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 μg paricalcitol
Number of subjects: 36
Study 31370809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29017972 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry reference equations for men
Number of subjects: 407
Study 29017972 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry reference equations for women
Number of subjects: 407
Study 29017972 — intervention group
Group type: COMPARATOR
Intervention: Comparison of spirometric values with lowland population
Number of subjects: 407
Study 29017972 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and height as predictors
Number of subjects: 407
Study 29017972 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear decline of FVC and FEV1 with age
Number of subjects: 407
Study 26325514 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2 to 0.7 μg/kg/h)
Number of subjects: 139
Study 26325514 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (0.08 to 0.15 μg/kg/min)
Number of subjects: 139
Study 23722111 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) with an IMT load
Number of subjects: 31
Study 23722111 — intervention group
Group type: COMPARATOR
Intervention: Placebo (negligible inspiratory resistance)
Number of subjects: 31
Study 23722111 — intervention group
Group type: COMPARATOR
Intervention: Control (no IMT device or soccer training)
Number of subjects: 31
Study 22348112 — intervention group
Group type: EXPERIMENTAL
Intervention: Full personalized normative feedback intervention
Number of subjects: 0
Study 22348112 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial feedback (without norms)
Number of subjects: 0
Study 22348112 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 0
Study 20145556 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate static stretching (SS) for knee flexors, 3-minute protocol
Number of subjects: 29
Study 20145556 — intervention group
Group type: COMPARATOR
Intervention: Control condition (sitting for 10 minutes)
Number of subjects: 29
Study 18056490 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block (20 mL of 0.5% bupivacaine) along with standard pain management
Number of subjects: 54
Study 18056490 — intervention group
Group type: COMPARATOR
Intervention: Standard pain management alone (typically intravenous narcotics)
Number of subjects: 54
Study 15749490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm treatment with exogenous PAF (10(‐7) mol/L) in sperm-washing medium, direct swim-up technique, maximum of six IUI cycles
Number of subjects: 52
Study 15749490 — intervention group
Group type: COMPARATOR
Intervention: Direct swim-up technique without PAF treatment
Number of subjects: 52
Study 12131185 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus HAART (9 megaunits daily for 5 days in 6-week intervals for a total of eight cycles)
Number of subjects: 56
Study 12131185 — intervention group
Group type: COMPARATOR
Intervention: HAART alone (stavudine, lamivudine, nelfinavir, saquinavir)
Number of subjects: 56
Study 12131185 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus HAART
Number of subjects: 56
Study 11908371 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Actibrush battery‐powered toothbrush
Number of subjects: 61
Study 11908371 — intervention group
Group type: COMPARATOR
Intervention: CrossAction Toothbrush
Number of subjects: 61
Study 8961775 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day selegiline
Number of subjects: 24
Study 8961775 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day selegiline
Number of subjects: 24
Study 8961775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1553901 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicine N-oxide at 2,000 mg/m2/day for 5 consecutive days
Number of subjects: 46
Study 1553901 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicine N-oxide at 2,500 mg/m2/day for 5 consecutive days
Number of subjects: 46
Study 1553901 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicine N-oxide
Number of subjects: 46
Study 3964332 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation A (hard gelatine capsule with pellets)
Number of subjects: 12
Study 3964332 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation B (soft gelatine capsule with liquid nifedipine)
Number of subjects: 12
Study 3964332 — intervention group
Group type: COMPARATOR
Intervention: Preparation C (retard-tablet)
Number of subjects: 12
Study 3964332 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dosing of nifedipine
Number of subjects: 12
Study 31373068 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (Btx type B)
Number of subjects: 8
Study 31373068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31373068 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (Btx type B) (open label after placebo)
Number of subjects: 8
Study 29384243 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 202
Study 29384243 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 202
Study 29384243 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with urine albumin excretion ≥7 mg/d
Number of subjects: 202
Study 29384243 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with urine albumin excretion <7 mg/d
Number of subjects: 202
Study 29384243 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 202
Study 26774708 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilamellar tarsal rotation (BLTR) surgery
Number of subjects: 1000
Study 26774708 — intervention group
Group type: COMPARATOR
Intervention: Posterior lamellar tarsal rotation (PLTR) surgery
Number of subjects: 1000
Study 26774708 — intervention group
Group type: COMPARATOR
Intervention: Comparison of BLTR vs PLTR
Number of subjects: 1000
Study 24670332 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic vibration-exposed workers
Number of subjects: 31
Study 24670332 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 31
Study 22996849 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injections of local anesthetic (lidocaine 0.5%)
Number of subjects: 100
Study 22996849 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with 0.5% lidocaine mixed with 1 mL of steroid (6 mg non-particulate betamethasone)
Number of subjects: 100
Study 20577774 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-pulsed 532 nm Medlite IV laser (10 ns, 1 J/cm²)
Number of subjects: 17
Study 20577774 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulsed 532 nm Aura laser (10 ms, 1 J/cm²)
Number of subjects: 17
Study 20577774 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 17
Study 17921369 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (65% carbohydrate, 13% protein, 22% fat)
Number of subjects: 100
Study 17921369 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (48% carbohydrate, 19% protein, 33% fat)
Number of subjects: 100
Study 16126058 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term transfusion (CTX)
Number of subjects: 94
Study 16126058 — intervention group
Group type: COMPARATOR
Intervention: Standard care (STC)
Number of subjects: 94
Study 16126058 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 94
Study 12209526 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (100 mg, 200 mg)
Number of subjects: 60
Study 12209526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12209526 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 60
Study 10074879 — intervention group
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 1
Study 7747322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (200 or 400 micrograms/kg)
Number of subjects: 67
Study 7747322 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC, 6 mg/kg)
Number of subjects: 67
Study 7747322 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ivermectin (20 micrograms/kg) followed 4 d later by DEC (6 mg/kg)
Number of subjects: 67
Study 2153393 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (cyclophosphamide 1 g m‐2 i.v. day 1, vincristine 2 mg i.v. day 1, etoposide 100 mg tds p.o. days 1‐3, repeated every 21 days)
Number of subjects: 19
Study 2153393 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 19
Study 28986814 — intervention group
Group type: EXPERIMENTAL
Intervention: Shen-Fu Injection (SFI), 100 mL intravenously every 12 h
Number of subjects: 65
Study 28986814 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment including volume resuscitation, antibiotics, and vasoactive drugs)
Number of subjects: 65
Study 28098515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZ) 10 mg/day
Number of subjects: 41
Study 28098515 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant Sterol (PS) 2 g/day
Number of subjects: 41
Study 28098515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe + Plant Sterol (EZ+PS) 10 mg/day + 2 g/day
Number of subjects: 41
Study 28098515 — intervention group
Group type: COMPARATOR
Intervention: Control (CT) group on same statin therapy
Number of subjects: 41
Study 26125572 — intervention group
Group type: EXPERIMENTAL
Intervention: Back massage (BM) intervention for 5 consecutive days
Number of subjects: 60
Study 26125572 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 60
Study 23613027 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health worker (LHW) intervention
Number of subjects: 260
Study 23613027 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 260
Study 22310864 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive pictorial education plus information booklet
Number of subjects: 136
Study 22310864 — intervention group
Group type: EXPERIMENTAL
Intervention: Education only with information booklet
Number of subjects: 136
Study 22310864 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 136
Study 19185647 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin for 1 year
Number of subjects: 1816
Study 19185647 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin for 1 year
Number of subjects: 1816
Study 18036086 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 19
Study 18036086 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 19
Study 15027183 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy group (148 cases)
Number of subjects: 258
Study 15027183 — intervention group
Group type: COMPARATOR
Intervention: Control group (110 cases)
Number of subjects: 258
Study 11883256 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanins
Number of subjects: 38
Study 11883256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 11883256 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy males)
Number of subjects: 38
Study 9590187 — intervention group
Group type: EXPERIMENTAL
Intervention: ABLC (5 mg/kg/d)
Number of subjects: 0
Study 9590187 — intervention group
Group type: COMPARATOR
Intervention: AmB (0.6 to 1 mg/kg)
Number of subjects: 0
Study 9590187 — intervention group
Group type: EXPERIMENTAL
Intervention: ABLC
Number of subjects: 0
Study 8147064 — intervention group
Group type: EXPERIMENTAL
Intervention: One balloon inflation (group A, n = 167)
Number of subjects: 300
Study 8147064 — intervention group
Group type: EXPERIMENTAL
Intervention: Three balloon inflations (group B, n = 168)
Number of subjects: 300
Study 8147064 — intervention group
Group type: COMPARATOR
Intervention: Three balloon inflations (group B1, n = 111)
Number of subjects: 300
Study 8147064 — intervention group
Group type: COMPARATOR
Intervention: One balloon inflation (group A1, n = 70)
Number of subjects: 300
Study 3049485 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of naproxen sodium
Number of subjects: 54
Study 3049485 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of naproxen sodium
Number of subjects: 54
Study 3049485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 3049485 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 54
Study 29636047 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 60
Study 27912986 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Number of subjects: 0
Study 27912986 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM vaccine
Number of subjects: 0
Study 27912986 — intervention group
Group type: COMPARATOR
Intervention: 4CMenB and MenACWY-CRM vaccines
Number of subjects: 0
Study 26882604 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Huoxue Qingre Huashi Recipe (YHQHR), twice per day for 6 successive weeks, in addition to standard triple therapy.
Number of subjects: 80
Study 26882604 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy alone (control group) plus omeprazole enteric coated tablet, 20 mg once per day for 4 weeks.
Number of subjects: 80
Study 26882604 — intervention group
Group type: EXPERIMENTAL
Intervention: YHQHR combined with standard triple therapy.
Number of subjects: 80
Study 26882604 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy alone (control group).
Number of subjects: 80
Study 23042930 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-FLAIR
Number of subjects: 37
Study 23042930 — intervention group
Group type: COMPARATOR
Intervention: 3D-DIR
Number of subjects: 37